Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Girentuximab |
Synonyms | |
Therapy Description |
Rencarex (Girentuximab) is a monoclonal antibody that targets G250, an antigen expressed by renal cell carcinoma cells, with potential utility as a carrier for other therapeutic agents (PMID: 30487460). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Girentuximab | Rencarex | WX-G250|chimeric monoclonal antibody cG250 | Rencarex (Girentuximab) is a monoclonal antibody that targets G250, an antigen expressed by renal cell carcinoma cells, with potential utility as a carrier for other therapeutic agents (PMID: 30487460). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00717587 | Phase II | Sunitinib Girentuximab Motexafin gadolinium | Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer | Unknown status | USA | 0 |